Bradley Haverkos, MD
Hematology & Oncology · Aurora, CONPI 1679707319
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $95,375 of the $120,386 with a category attached, or 79.2%. 21 manufacturers reported payments, led by Kyowa Kirin, Inc. at 32.2% of the total. Reporting peaked in 2022 at $37,155 and has fallen 61.5% since, to $14,315 in 2025. Among hematology & oncology clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 130 payments — averaging $926.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kyowa Kirin, Inc.$39K
- ADC Therapeutics America, Inc.$24K
- Acrotech Biopharma Inc.$17K
- Seagen Inc.$12K
- Genentech, Inc.$6K
- Pierre Fabre Pharmaceuticals, Inc.$5K
- plus $18K from 15 others
Across 134 payments — averaging $7095.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$425K
- Daiichi Sankyo Inc.$346K
- Taiho Oncology, Inc.$114K
- Otsuka Pharmaceutical Co., Ltd.$66K
- Merck$265
What the payments were for
- Consulting fees$95,37579%
- Speaking & faculty fees$13,27811%
- Travel & lodging$7,0426%
- Food & beverage$4,6914%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kyowa Kirin, Inc. | 21 | $38,750 |
| ADC Therapeutics America, Inc. | 16 | $24,061 |
| Acrotech Biopharma Inc. | 26 | $17,037 |
| Seagen Inc. | 18 | $11,691 |
| Genentech, Inc. | 6 | $6,260 |
| Pierre Fabre Pharmaceuticals, Inc. | 8 | $4,886 |
| Gilead(2 entities) | 11 | $4,881 |
| Verastem, Inc. | 3 | $4,184 |
| Aurobindo Pharma USA, Inc. | 5 | $2,320 |
| Daiichi Sankyo Inc. | 1 | $2,031 |
| Incyte Corporation | 3 | $1,878 |
| Karyopharm Therapeutics Inc. | 2 | $1,070 |
| Sanofi-aventis U.S. LLC | 1 | $500 |
| AstraZeneca | 1 | $245 |
| Spectrum Pharmaceuticals Inc. | 2 | $201 |
| Taiho Oncology, Inc. | 1 | $163 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $125 |
| Adaptive Biotechnologies Corporation | 1 | $45 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $26 |
| AbbVie | 1 | $17 |
| Terumo BCT, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$120,386 in reported general payments places this provider in the 90th percentile of 169 hematology & oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RezurockBelumosudil Mesylate | 13 | $446,443 |
| Bexarotene | 144 | $413,335 |
| BrukinsaZanubrutinib | 13 | $195,384 |
| ZolinzaVorinostat | 19 | $153,677 |
| PegasysPeginterferon Alfa-2a | 36 | $80,918 |
| Acitretin | 18 | $3,119 |
| SynthroidLevothyroxine Sodium | 17 | $1,283 |
| Acyclovir | 94 | $1,211 |
| Fluconazole | 20 | $1,059 |
| Levothyroxine Sodium | 80 | $1,043 |
| Rosuvastatin Calcium | 38 | $423 |
| Gabapentin | 11 | $392 |
| MethotrexateMethotrexate Sodium | 14 | $298 |
| Atorvastatin Calcium | 12 | $186 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 32 | $144 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sanofi-aventis U.S. LLCRezurock | $500 | $446,44313 claims |
| Genentech, Inc.Pegasys | $6,260 | $80,91836 claims |
| AbbVieSynthroid | $17 | $1,28317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 169 hematology & oncology providers in Colorado.
Other hematology & oncology in Aurora
- John BurkeAurora$321K
- Douglas ReznickAurora$294K
- Daniel PollyeaAurora$274K
- Sami DiabAurora$134K
- Manali KamdarAurora$129K
- Sujatha NallapareddyAurora$112K
- Tomer MarkAurora$96K
- Ara MetjianAurora$89K
- Ryan WeightAurora$65K
- Breelyn WilkyAurora$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.